Amgen Boosts Outlook on Rising Drug Sales as Competition Looms

TL;DR

Reports differ across sources; according to finance.yahoo.com, key Points - Amgen said it delivered a “strong” Q1 with its six key growth drivers accounting for nearly 70% of sales and growing 24% collectively, with standout product momentum such as Repatha +34%, Evenity +27%, TEPEZZA +29%, and a rare-disease portfolio up 25% (Uplizna +188%).